Infectious Complications of CAR T-Cell Therapy in Non-Hodgkin Lymphoma

The objective of this study was to identify rates of infectious complications and febrile neutropenia at our institution. This retrospective single center study included 38 patients with relapsed, refractory non-Hodgkin lymphoma (NHL), who received CD19 directed CAR T-cell therapy axicabtagene ciloleucel, as standard of care for the treatment relapsed NHL between January, 2018 and October, 2019.

https://www.bbmt.org/article/S1083-8791(19)31375-8/fulltext?rss=yes

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Justin Hayne, Jilan Kubusek, Pritish K. Tosh, Nora N. Bennani, Yi Lin, Stephen Ansell, Jose Villasboas Bisneto, Adrienne Nedved, Jonas Paludo, Patrick B. Johnston Tags: 415 Source Type: research